BiotechTube

RAD001: Everolimus

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis Type 1

Conditions

Neurofibromatosis Type 1, Plexiform Neurofibroma, Neurofibromatoses

Trial Timeline

Apr 1, 2011 → Oct 1, 2014

NCT ID
NCT01412892

About RAD001: Everolimus

RAD001: Everolimus is a phase 2 stage product being developed by Novartis for Neurofibromatosis Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT01412892. Target conditions include Neurofibromatosis Type 1, Plexiform Neurofibroma, Neurofibromatoses.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01412892Phase 2Completed

Competing Products

20 competing products in Neurofibromatosis Type 1

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
52
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
33
AZD2014AstraZenecaPhase 2
52
Selumetinib + PlaceboAstraZenecaPhase 2
52
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 3
77
Everolimus (RAD001) , Afinitor®NovartisPhase 2
52
RAD001, everolimusNovartisPhase 2
52
TasignaNovartisPhase 1
33
TrametinibNovartisPhase 2
52
Everolimus (RAD001)NovartisPhase 2
52
Sutent®/SunitinibPfizerPhase 2
51
Sorafenib (Nexavar)BayerPhase 2
49
PTC299United TherapeuticsPhase 2
49
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
60
BinimetinibPacific BiosciencesPhase 2
44

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85